| __timestamp | Pharming Group N.V. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4042025 | 59644696 |
| Thursday, January 1, 2015 | 5279557 | 79541000 |
| Friday, January 1, 2016 | 8073913 | 98015000 |
| Sunday, January 1, 2017 | 44864073 | 103958000 |
| Monday, January 1, 2018 | 53488904 | 103654000 |
| Tuesday, January 1, 2019 | 65896361 | 128951000 |
| Wednesday, January 1, 2020 | 69968267 | 135799000 |
| Friday, January 1, 2021 | 92047281 | 149883000 |
| Saturday, January 1, 2022 | 131819000 | 220206000 |
| Sunday, January 1, 2023 | 87501000 | 265542000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Pharming Group N.V. and Travere Therapeutics, Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, Pharming Group N.V. maintained a relatively stable SG&A expense growth, peaking in 2022 with a 130% increase from 2014. In contrast, Travere Therapeutics, Inc. experienced a more aggressive rise, with expenses surging by over 340% during the same period, reaching their highest in 2023. This disparity highlights different strategic priorities: while Pharming focuses on steady growth, Travere invests heavily in expansion. Understanding these trends offers valuable insights into each company's operational strategies and financial health, providing investors with a clearer picture of their potential for sustainable growth.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Novartis AG vs Pharming Group N.V. Trends and Insights
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.